---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007080"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T17:40:31.042358+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 reduces oxidative stress in human retinal cells, advancing potential AMD treatment

## Summary
- Telomir-1 significantly reduced reactive oxygen species (ROS) elevation from copper and iron exposure in human retinal cell lines.
- Compound showed strong ROS regulation at low concentrations, suggesting a regulatory effect beyond metal chelation.
- Study targets age-related macular degeneration (AMD) and other retinal diseases linked to oxidative stress.
- Company initiating AMD disease models to evaluate in vivo efficacy and support potential clinical development.

## SEC filing metadata
- accession: 0001493152-25-007080
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225007080/0001493152-25-007080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225007080/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007080
- JSON: https://secwatch.observer/filing/0001493152-25-007080.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.